Renin-angiotensin system and urological cancers;Système rénine-angiotensine et cancers urologiques

Progres en Urologie

Volumn 24, Issue 2, 2014, Pages 73-79

  Verhoest, G ^a,b   Dolley Hitze, T ^a,b   Jouan, F ^b   Bensalah, K ^a   Arlot Bonnemains, Y ^b   Dugay, F ^a,b   Belaud Rotureau, M A ^a,b   Rioux Leclercq, N ^a,b   Vigneau, C ^a,b  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Angiogenesis; Antagonists of angiotensin II receptors; AT1R; Inhibitors of angiotensinogen converting enzyme; VEGF

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ANGIOGÉNÈSE; ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II; ANTAGONISTS OF ANGIOTENSIN-II RECEPTORS; AT1R; HUMAN; INHIBITEURS DE L'ENZYME DE CONVERSION; INHIBITORS OF ANGIOTENSINOGEN CONVERTING ENZYME; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; URINARY TRACT CANCER;

ANGIOGENESIS; ANGIOGÉNÈSE; ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II; ANTAGONISTS OF ANGIOTENSIN-II RECEPTORS; AT1R; INHIBITEURS DE L'ENZYME DE CONVERSION; INHIBITORS OF ANGIOTENSINOGEN CONVERTING ENZYME; VEGF;

HUMANS; RENIN-ANGIOTENSIN SYSTEM; UROLOGIC NEOPLASMS;

EID: 84895906350     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2013.09.010     Document Type: Short Survey

References (59)

1. Dolley-Hitze T., Verhoest G., Jouan F., Le Pogamp P., Arlot-Bonnemains Y., Oger E., et al. Récepteurs de type 1à l'angiotensine-2 (AT1R) et cancers. Nephrol Ther 2013, 9:85-91.
2. Sipahi I., Debanne S.M., Rowland D.Y., Simon D.I., Fang J.C. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010, 11:627-636.
3. Sipahi I., Chou J., Mishra P., Debanne S.M., Simon D.I., Fang J.C. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am J Cardiol 2011, 108:294-301.
4. ARB Trialists Collaboration Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15trials enrolling 138,769, individuals. J Hypertens 2011, 29:623-635.
5. Meredith P.A., McInnes G.T. Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncol 2010, 11:819.
6. Lever A.F., Hole D.J., Gillis C.R., McCallum I.R., McInnes G.T., MacKinnon P.L., et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet 1998, 352:179-184.
7. Huang C.C., Chan W.L., Chen Y.C., Chen T.J., Lin S.J., Chen J.W., et al. Angiotensine II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol 2011, 107:1028-1033.
8. Wilop S., von Hobe S., Crysandt M., Esser A., Osieka R., Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 2009, 135:1429-1435.
9. Chae Y.K., Valsecchi M.E., Kim J., Bianchi A.L., Khemasuwan D., Desai A., et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 2011, 29:585-593.
10. Keizman D., Huang P., Eisenberger M.A., Pili R., Kim J.J., Antonarakis E.S., et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer 2011, 47:1955-1961.
11. Neuzillet Y., Delbado C. Les voies anti-angiogéniques du futur. Prog Urol 2011, 21(Suppl 2):S13-S15.
12. Ravaud A. Le mécanisme de l'angiogenèse tumorale. Prog Urol 2007, 17(1Suppl. 1):144-147.
13. George A.J., Thomas W.G., Hannan R.D. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 2010, 10:745-759.
14. Norwood V.F., Craig M.R., Harris J.M., Gomez R.A. Differential expression of angiotensin II receptors during early renal morphogenesis. Am J Physiol 1997, 272:R662-R668.
15. Oro C., Qian H., Thomas W.G. Type 1angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther 2007, 113:210-226.
16. Hunyady L., Catt K.J. Pleiotropic AT1receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006, 20:953-970.
17. Smith N.J., Chan H.W., Osborne J.E., Thomas W.G., Hannan R.D. Hijacking epidermal growth factor receptors by angiotensin II: new possibilities for understanding and treating cardiac hypertrophy. Cell Mol Life Sci 2004, 61:2695-2703.
18. Suzuki K., Han G.D., Miyauchi N., Hashimoto T., Nakatsue T., Fujioka Y., et al. Angiotensine II type 1and type 2receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol 2007, 170:1841-1853.
19. Arrieta O., Pineda-Olvera B., Guevara-Salazar P., Hernandez-Pedro N., Morales-Espinosa D., Ceron-Lizarraga T.L., et al. Expression of AT1and AT2angiotensin receptors in astrocytomas is associated with poor prognosis. Br J Cancer 2008, 99:160-166.
20. Dolley-Hitze T., Jouan F., Martin B., Mottier S., Edeline J., Moranne O., et al. Angiotensin-2receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?. Br J Cancer 2010, 103:1698-1705.
21. Rocken C., Rohl F.W., Diebler E., Lendeckel U., Pross M., Carl-McGrath S., et al. The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:1206-1212.
22. Anandanadesan R., Gong Q., Chipitsyna G., Witkiewicz A., Yeo C.J., Arafat H.A., et al. Angiotensine II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1receptor and ERK1/2signaling. J Gastrointest Surg 2008, 12:57-66.
23. Kosugi M., Miyajima A., Kikuchi E., Kosaka T., Horiguchi Y., Murai M. Effect of angiotensin II type 1receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer. Hum Cell 2007, 20:1-9.
24. Zhao Y., Chen X., Cai L., Yang Y., Sui G., Fu S. Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7breast cancer cells survival via PI3-kinase/Akt pathway. J Cell Physiol 2010, 225:168-173.
25. Kinoshita J., Fushida S., Harada S., Yagi Y., Fujita H., Kinami S., et al. Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. Int J Oncol 2009, 34:1573-1582.
26. Bose S.K., Gibson W., Giri S., Nath N., Donald C.D. Angiotensine II up-regulates PAX2oncogene expression and activity in prostate cancer via the angiotensin II type I receptor. Prostate 2009, 69:1334-1342.
27. Fujiyama S., Matsubara H., Nozawa Y., Maruyama K., Mori Y., Tsutsumi Y., et al. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 2001, 88:22-29.
28. Greco S., Muscella A., Elia M.G., Salvatore P., Storelli C., Mazzotta A., et al. Angiotensine II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 2003, 196:370-377.
29. Uemura H., Ishiguro H., Nakaigawa N., Nagashima Y., Miyoshi Y., Fujinami K., et al. Angiotensine II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003, 2:1139-1147.
30. Ohashi H., Takagi H., Oh H., Suzuma K., Suzuma I., Miyamoto N., et al. Phosphatidylinositol 3-kinase/Akt regulates angiotensin II-induced inhibition of apoptosis in microvascular endothelial cells by governing survivin expression and suppression of caspase-3activity. Circ Res 2004, 94:785-793.
31. Herr D., Rodewald M., Fraser H.M., Hack G., Konrad R., Kreienberg R., et al. Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol 2008, 109:418-425.
32. Arafat H.A., Gong Q., Chipitsyna G., Rizvi A., Saa C.T., Yeo C.J. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 2007, 204:996-1005.
33. Huang W., Wu Y.L., Zhong J., Jiang F.X., Tian X.L., Yu L.F. Angiotensin II, type 1receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts. Dig Dis Sci 2008, 53:1206-1210.
34. Neo J.H., Ager E.I., Angus P.W., Zhu J., Herath C.B., Christophi C. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer 2010, 10:134.
35. Wasa J., Sugiura H., Kozawa E., Kohyama K., Yamada K., Taguchi O. The tumor suppressive effect of angiotensin II type 1receptor antagonist in a murine osteosarcoma model. Anticancer Res 2011, 31:123-127.
36. Otake A.H., Mattar A.L., Freitas H.C., Machado C.M., Nonogaki S., Fujihara C.K., et al. Inhibition of angiotensin II receptor 1limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemother Pharmacol 2010, 66:79-87.
37. Du N., Feng J., Hu L.J., Sun X., Sun H.B., Zhao Y., et al. Angiotensine II receptor type 1blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. Oncol Rep 2012, 27:1893-1903.
38. Wang L., Cai S.R., Zhang C.H., He Y.L., Zhan W.H., Wu H., et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. Chin Med J (Engl) 2008, 121:2167-2171.
39. Gong Q., Davis M., Chipitsyna G., Yeo C.J., Arafat H.A. Blocking angiotensin II Type 1receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas 2010, 39:581-594.
40. Arnold S.A., Rivera L.B., Carbon J.G., Toombs J.E., Chang C.L., Bradshaw A.D., et al. Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFbeta activation. PLoS One 2012, 7:e31384.
41. Chehl N., Gong Q., Chipitsyna G., Aziz T., Yeo C.J., Arafat H.A., et al. Angiotensine II regulates the expression of monocyte chemoattractant protein-1in pancreatic cancer cells. J Gastrointest Surg 2009, 13:2189-2200.
42. Spychalowicz A., Wilk G., Sliwa T., Ludew D., Guzik T.J. Novel therapeutic approaches in limiting oxidative stress and inflammation. Curr Pharm Biotechnol 2012, 13:2456-2466.
43. Kohl R.R., Kolozsvary A., Brown S.L., Zhu G., Kim J.H. Differential radiation effect in tumor and normal tissue after treatment with ramipril, an angiotensin-converting enzyme inhibitor. Radiat Res 2007, 168:440-445.
44. Yanase K., Yoshiji H., Ikenaka Y., Noguchi R., Kitade M., Kaji K., et al. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep 2007, 17:441-446.
45. Noguchi R., Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Yanase K., et al. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 2003, 9:6038-6045.
46. Noguchi R., Yoshiji H., Ikenaka Y., Namisaki T., Kitade M., Kaji K., et al. Synergistic inhibitory effect of gemcitabine and angiotensin type-1receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol Rep 2009, 22:355-360.
47. Fendrich V., Chen N.M., Neef M., Waldmann J., Buchholz M., Feldmann G., et al. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 2010, 59:630-637.
48. Deshayes F., Nahmias C. Angiotensin receptors: a new role in cancer?. Trends Endocrinol Metab 2005, 16:293-299.
49. Li H., Qi Y., Li C., Braseth L.N., Gao Y., Shabashvili A.E., et al. Angiotensin type 2receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther 2009, 8:3255-3265.
50. Kosaka T., Miyajima A., Shirotake S., Kikuchi E., Hasegawa M., Mikami S., et al. Ets-1and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1receptor blockade in hormone-refractory prostate cancer. Prostate 2010, 70:162-169.
51. Kosaka T., Miyajima A., Takayama E., Kikuchi E., Nakashima J., Ohigashi T., et al. Angiotensine II type 1receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007, 67:41-49.
52. Uemura H., Hasumi H., Kawahara T., Sugiura S., Miyoshi Y., Nakaigawa N., et al. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 2005, 10:405-410.
53. Kosugi M., Miyajima A., Kikuchi E., Horiguchi Y., Murai M. Angiotensin II, type 1receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 2006, 12:2888-2893.
54. Kosugi M., Miyajima A., Kikuchi E., Kosaka T., Horiguchi Y., Murai M., et al. Angiotensin II, type 1receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer. Urology 2009, 73:655-660.
55. Fergelot P., Rioux-Leclercq N., Patard J.J. Voies moléculaires de l'angiogenèse tumorale et nouvelles approches thérapeutiques ciblées dans le cancer du rein. Prog Urol 2005, 15:1021-1029.
56. Hii S.I., Nicol D.L., Gotley D.C., Thompson L.C., Green M.K., Jonsson J.R. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998, 77:880-883.
57. Miyajima A., Kosaka T., Asano T., Seta K., Kawai T., Hayakawa M. Angiotensin II, type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002, 62:4176-4179.
58. Verhoest G., Dolley-Hitze T., Jouan F., Bensalah K., Belaud-Rotureau M.A., Rioux-Leclercq N., et al. Efficacité des antagonistes des récepteurs de type 1de l'angiotensine II en association aux inhibiteurs de tyrosine kinase dans un modèle murin de xénogreffe de carcinome rénal à cellules claires. Prog Urol 2011, 21:732-734.
59. Becker B.N., Kondo S., Chen J.K., Harris R.C. Tyrosine kinase inhibition affects type 1angiotensin II receptor internalization. J Recept Signal Transduct Res 1999, 19:975-993.